Relationships between clinical manifestations, knee histopathology, and life quality in patients with grade 3-4 gonarthrosis

e18004 Background: Despite recent improvements, toxicities in B-cell lymphoma patients during treatment remains a major challenge for leukemia community. The aim of this study was to determine factors affecting the hematological and non-hematological toxicities in B-cell lymphoma patients during treatment. Methods: This multicentral cross-sectional study was performed on 68 diagnosed B-cell lymphoma patients (17–72 y/o, mean age 53y/o) admitted in three cancer centers for treatment during 2003–2008. Patients with other malignancies, serious illness or infection were not included. Demographic data, clinical and para clinical manifestations were recorded during treatment. Results: 31 (45%) patients developed grade 2 or greater non-hematological toxicities: 11:fever, 8:chills, 6:vomiting, 4:rash, and 3:pruritus. Moreover, 7 patients developed grade 3 non-hematological toxicities. 42 (62%) patients developed grade 2 or greater hematological toxicities. Non-hematological toxicities were more frequent in patients with BM (Bone Marrow) involvement [15/32 (47%) versus 21/60 (35%), p = 0.01] and with extranodal disease [23/48 (48%) versus 11/42 (26%), p = 0.008]. The incidence of grade 3 or 4 hematological toxicity was higher in females than males [17/43 (40%) versus 13/50 (26%), p = 0.001]. Furthermore, being female was significantly associated with the development of grade 3 or 4 neutropenia [17/49 (35%) versus 8/53 (15%), p = 0.003]. In addition, high LDH was also associated with grade 3 or 4 leukopenia [7/27 (26%) versus 9/58 (16%), p = 0.01], but not with neutropenia. Conclusions: Multivariate analysis demonstrate that some factors like female gender, BM involvement, and serum LDH level could be useful for predicting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment. No significant financial relationships to disclose.

Download Full-text

The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease

Gastroenterology Research and Practice ◽

10.1155/2013/419375 ◽

2013 ◽

Vol 2013 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Ying Chen ◽

Feng Wang ◽

Yuanxi Jiang ◽

Chen Wang ◽

Liwen Yao ◽

...

Keyword(s):

Gastroesophageal Reflux Disease ◽

Gastroesophageal Reflux ◽

Reflux Disease ◽

Low Cost ◽

Clinical Manifestations ◽

Life Quality ◽

Diagnostic Significance ◽

Sf 36 ◽

Before And After

Gastroesophageal reflux disease is a diversity disease that affects life quality of people in the world. Due to the complicated pathogenesis and variations in clinical manifestations, there is still no true gold standard for GERD diagnosis, and it is still difficult to diagnose this disease in some patients. The proton pump inhibitor’s diagnostic test (the PPI test) is noninvasive, of low cost, tied to treatment, and widely accepted. Our aim is to evaluate the diagnostic significance of coapplying a rabeprazole test with the SF-36 for GERD in this study. Our study shows that the SF-36 in combination with the rabeprazole test can screen GERD patients and increase the sensitivity and specificity of GERD diagnosis through reference to the change in SF-36 score before and after the treatment (65 in the trial).

Download Full-text

1% ivermectin in combination therapy regimens for rosacea

Medical Council ◽

10.21518/2079-701x-2020-12-17-23 ◽

2020 ◽

pp. 17-23

Author(s):

E. A. Khlystova ◽

A. L. Savastenko

Keyword(s):

Quality Of Life ◽

Comparative Analysis ◽

Combination Therapy ◽

Combination Treatment ◽

Clinical Manifestations ◽

Life Quality ◽

Clinical Results ◽

Control Group ◽

Before And After

Introduction. The article provides latest data on modern methods of treating rosacea. The results of own clinical observations of patients with moderate to severe papulopustular rosacea receiving combination treatment and a comparative analysis of the efficacy of various therapy regimens are presented.Objective of the study. The aim of the study was to conduct a comparative analysis of the therapeutic efficacy of combination therapy using the ivermectin 1% topical drug combined with systemic therapy drugs (doxycycline, minocycline, isotretinoin).Materials and methods. We observed 37 patients with moderate to severe papulo-pustular rosacea subtype. The patients were divided into 4 groups (A, B, C, D). Patients in the control group received monotherapy with 1% ivemectin topical drug, patients in the other groups received combination therapy (1% ivermectin combined with low-dose doxycycline, minocycline and isotretinoin). The efficacy of the therapy was evaluated by measuring rosacea severity on the Scale for Diagnostic Assessment of Rosacea (SDAR), clinical manifestations according to the IGA (Investigator Global Assessment) criteria, and by assessing the patients' quality of life using the DLQI (Dermatology Life Quality Index) questionnaire before and after 3-month treatment.Results. The comparative analysis of changes in severity indicators of the skin process and quality of life in patients with moderate to severe papulopustular rosacea after topical and combination therapy showed that the results of the treatment in patients receiving combination therapy were more significant than those in the group receiving monotherapy.Conclusion. The concomitant use of 1% ivermectin and systemic drugs is most effective in patients with severe papulopustular rosacea subtype. The combination treatment tailored to the clinical forms and severity of rosacea allows to optimize the clinical results of the therapy, which significantly affects the patients' quality of life and opens up potential for an individual approach in the algorithms for the treatment of rosacea.

Download Full-text

Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis

Journal of Oncology ◽

10.1155/2021/6631643 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Zexi Xu ◽

Jia Feng ◽

Yiming Weng ◽

Yao Jin ◽

Min Peng

Keyword(s):

Prostate Cancer ◽

Lung Cancer ◽

Cell Lung Cancer ◽

Immune Checkpoint ◽

Fixed Effects ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Meta Analysis ◽

Clinical Manifestations ◽

Grade 3

Objectives. Immune checkpoint inhibitors (ICI) combined with radiotherapy (RT) have emerged as a breakthrough therapy in the treatment of various cancers. The combination has a strong rationale, but data on their efficacy and safety are still limited. Hence, we comprehensively searched the database and performed this study to elucidate the clinical manifestations of this combined strategy. Methods. We performed a meta-analysis of randomized trials that compared ICI plus RT with placebo plus RT or ICI alone for the treatment of advanced nonsmall-cell lung cancer (NSCLC) and prostate cancer. The outcomes included overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and treatment-related adverse events. A fixed-effects or random-effects model was adopted depending on between-study heterogeneity. Results. Three trials involving 1584 patients were included. ICI plus RT was significantly associated with improvement of OS (hazard ratio [HR] = 0.81, 95% confidence interval [CI] = 0.70–0.94, P = 0.004 ), PFS (HR = 0.64; 95% CI 0.56–0.72, P < 0.00001 ), and DCR (relative risk [RR] = 1.38; 95% CI 1.03–1.84, P = 0.03 ). A significant predictor for PFS with the combination of ICI and RT was age, as a significant improvement in PFS (HR = 0.49; 95% CI 0.37–0.64, P < 0.00001 ) was observed in NSCLC patients aged under 65 years. In safety analyses, patients receiving ICI plus RT had a significantly higher incidence of dyspnea (RR = 2.43; 95% CI 1.16–5.08, P = 0.02 ) and pneumonitis of grade 3 or higher (RR = 2.78; 95% CI 1.32–5.85, P = 0.007 ). Conclusion. The combination of ICI and RT was associated with improved OS, PFS, and DCR. Patients under 65 years will be the dominant beneficiaries. However, the incidence of dyspnea and pneumonia of grade 3 or higher also increased, which deserves our vigilance.

Download Full-text

Daily Monitoring of Cyclosporine (Csa) Allows Better Control of Graft vs. Leukaemia Effect (GvL): Single Centre Experience.

Blood ◽

10.1182/blood.v106.11.5319.5319 ◽

2005 ◽

Vol 106 (11) ◽

pp. 5319-5319

Author(s):

Mayukh Das ◽

Venkatasreekanth Sampath ◽

Margareta Angelica ◽

Angela Leather ◽

Mike Dennis ◽

...

Keyword(s):

Clinical Manifestations ◽

Therapeutic Index ◽

Daily Monitoring ◽

Significant Difference ◽

Close Observation ◽

Wide Variability ◽

First Occurrence ◽

Rsv Infection ◽

Grade 3 ◽

Full Intensity

Abstract The most important consideration in modern SCT practices is the fine balance that is required to achieve adequate immunosuppression and stable engraftment thus allowing the platform to mount an effective GVL response. Though CsA facilitates this objective, it is associated with several adverse clinical manifestations due to its narrow therapeutic index (TI) and wide variability in the absorption kinetics. Weekly monitoring of trough CsA levels are used to adjust the dose. The aim of this study is to determine whether daily monitoring of CsA levels enables better achievement of these goals and yet reduce the serious toxicities. Patients & methods: Twenty three patients (M=15, F=8, median age 46yrs range 19–63) received an allogeneic transplant (sibling-15, MUD-7 mismatched unrelated-1) since March 2004 when we started to monitor daily CsA levels (Biostat TDX analyser using fluorescent immunoassay) from the day of first administration until the time of discharge. The transplants included full intensity (FI=11), reduced intensity (RI=11) or customised (1) for various haematolymphoid malignancies. Patients received uniform GVHD prophylaxis with IV CsA (RI+FI) and methotrexate (FI) as per standard loading doses. The CsA target level was adjusted to 200–220 ng/ml from Day-1 onwards and was later modified according to the treatment strategy. Oral CsA administration was started when patients were able to switch over. Results Nine of 23 (40%) patients developed acute GVH (n=7 grade1–2, n=2 grade 3–4) at a median of 23.5 days (10–28). Two of 9 patients required addition of steroids by Day+30. The median CsA level at the first occurrence of GVH was 247ng/ml (113–333) and the median CsA level during hospitalisation was 207 ng/ml (136–291). Only one patient who received T cell addback required increased dose of IV CsA to manage Grade 4 GVH. Twenty two/22 patients engrafted with a median day to neutrophil recovery being 13 days (8–35). One patient lost his graft due to a low initial cell dose and the inability of the MUD donor to donate any further cells. There was no significant difference in the baseline and Day30 creatinine levels (median highest creatinine 108μmol/l range 58–267) or bilirubin levels (median highest bilirubin 27μmol/l, range15–251). Five/22 patients developed CMV reactivation/infection and 1 developed RSV infection. No patients developed seizures and in one patient pre-existent neuropathy was exacerbated which was directly attributable to CsA. Twenty one/22 patients (95.5%) switched to oral CsA by Day+25. In 8/22 (36.36%) patients, the target CsA levels was around 100–150 ng/ml at the time of discharge. The median duration of hospital stay was 35days (24–130). Conclusions: These observations suggests that daily monitoring of CsA is safe and successful. This allowed successful engraftment and a more liberal management of Grade 1–2 GVH thus allowing us to maximise the GVL effect. Despite concomitant use of other toxic drugs, side effects were minimal and reversible. Close observation of early clinical manifestations enabled us to modify the immunosuppressive strategy at later time periods. This approach also allowed us to better manage patients suffering from CMV and EBV/PTLD (patient number 10 on day+88) by reducing the dose during active infections.

Download Full-text

AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),

Blood ◽

10.1182/blood.v118.21.3820.3820 ◽

2011 ◽

Vol 118 (21) ◽

pp. 3820-3820

Author(s):

Naval Daver ◽

Hagop M. Kantarjian ◽

Guillermo Garcia-Manero ◽

Gautam Borthakur ◽

Farhad Ravandi ◽

...

Keyword(s):

Phase Ii ◽

Topoisomerase I ◽

Conflicts Of Interest ◽

Clinical Manifestations ◽

Median Number ◽

Dna Supercoiling ◽

Clinical Activity ◽

Hypomethylating Agent ◽

Blast Count ◽

Grade 3

Abstract Abstract 3820 Background: DNA topoisomerase I (TopoI) is an essential mammalian nuclear enzyme that relaxes DNA supercoiling generated by transcription, replication and chromatin remodeling. Topotecan and other Topo I inhibitors have shown clinical activity in MDS and CMML. AR-67 [(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin] is a third generation camptothecin analog that effectively inhibits topoisomerase I enzyme. Aim: This phase II study was conducted to estimate the efficacy and toxicity of AR-67 in patients with MDS, CMML or MDS/MPD who have failed prior therapies. Method: Subjects with MDS (>5% blasts, or IPSS risk group intermediate-1, intermediate-2 or high risk), CMML or MDS/MPD who had failed or were unable to receive therapy with either a hypomethylating agent (alone or in combination) or patients with abnormalities in chromosome 5q who failed either a hypomethylating agent or lenalidomide were eligible. Patients with performance status 0–2 with adequate organ function and no active, uncontrolled intercurrent illness or infection, receive AR-67 IV at 7.5 mg/m2 for 5 consecutive days every 4 weeks. Results: 10 patients with MDS, CMML or MDS/ MPD were enrolled (6 MDS, 2 CMML and 2 MDS/MPD). The median age was 69 years (yrs) (range, 52–83 yrs). All patients had received prior therapy with hypomethylating agents. The most common prior therapies included: azacytidine (n=6), decitabine (n=5) and clofarabine (n=5); either alone or in combination. The median number of prior therapies was 2 (range 1 to 4). Of the 6 MDS patients; 4 were IPSS Int-2 and 2 were IPSS Int-1. Both CMML patients were CMML-2. Cytogenetics analysis showed diploid karyotype in 4, trisomy 21 in 2, chromosome 7 abnormalities in 1, and various other abnormalities in 3. Molecular analysis showed NRAS mutation in 3 and FLT-3 ITD mutation in 1 patient. No patients had mutations in c-Kit, JAK-2 or NPM1. 9 of 10 enrolled patients received at least 1 dose of the AR-67. One patient was enrolled but withdrew prior to initiation of therapy. Median number of cycles received was 2 (1–6). Of the 9 patients treated, 1 patient had hematological response per IWG criteria. The hemoglobin improved from 8.1 g/dl to 11.5 g/dl, platelet count improved from 47 K/μL to 81 K/μL, peripheral blast count decreased from 4% to 1% and bone marrow blast count decreased from 9% to 5%. The response lasted 170 days. This patient also had a significant improvement in clinical manifestations associated with CMML, including fatigue, and incapacitating arthralgias allowing him to return to work. Two other patients had stable disease over 3 months and 2 months; respectively. The most common drug related adverse events were thrombocytopenia (5 overall; 3 grade 1–2; 2 grade 3), neutropenia (5 all grade 1–2), and anemia (5 all grade 1–2). Other noted adverse effects were diarrhea (4 overall; 3 grade 1–2, 1 grade 4), nausea (2 overall; 1 grade 2, 1 grade 3), elevated uric acid (2 overall; 1 grade 2, 1 grade 3), possible typhlitis (1 grade 3), mucositis (1 grade 1) and fatigue (1 grade 3, 1 grade 1). Dose reduction from 7.5 mg/m2 to 6.3 mg/m2 was required in 2 patients due to grade 3 fatigue and grade 3 thrombocytopenia; respectively. Conclusion: AR-67 administered at 7.5 mg/m2 showed efficacy and was tolerable in subjects with previously treated MDS, CMML or MDS/MPD. Myelosuppression is the most common toxicity, but is usually manageable. Additional studies of AR-67 in these disease groups are warranted. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

Nutritional status and life quality in patients undergoing bariatric surgery

ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) ◽

10.1590/s0102-6720201400s100009 ◽

2014 ◽

Vol 27 (suppl 1) ◽

pp. 35-38 ◽

Cited By ~ 8

Author(s):

Paulo Roberto Bezerra da SILVA ◽

Marcela Ramos de SOUZA ◽

Evane Moises da SILVA ◽

Silvia Alves da SILVA

Keyword(s):

Quality Of Life ◽

Bariatric Surgery ◽

Weight Loss ◽

Nutritional Status ◽

Positive Impact ◽

Clinical Manifestations ◽

Life Quality ◽

Excess Weight ◽

Global Epidemic

BACKGROUND: The obesity has achieved an alarming increase in recent years, which led this disease to global epidemic condition. AIM: To evaluate the nutritional status as well as the quality of life of obese patients undergoing bariatric surgery. METHODS: A transversal study was conducted with obese adults of both genders who underwent bariatric surgery by Fobi-Capella technique for at least 30 days. It was evaluated: age, gender, marital status, occupation, weight before surgery, current weight, height, preoperative and current BMI, weight loss and loss of excess weight percentages, presence of clinical manifestations and food intolerances. RESULTS: The sample consisted of 70 patients, being 81.4% female, 37.1% aged 30 to 39 years, 58.6% were married, 41.4% have undergone the bariatric surgery in the last 12 months. It was observed a reduction in BMI from 37.2 kg/m2 (one to three months) to 28.9 kg/m2 (>12 months) and consequent increase in weight loss and loss of excess weight percentages. The most frequent clinical manifestation was alopecia (62.9%). The most reported food intolerance was on the red meat (24%). According to the Baros questionnaire, 50% of patients were classified as having good quality of life. CONCLUSION: The operation of Fobi-Capella proved to be effective in promoting gradual and lasting weight loss. Quality of life was considered good in most patients, indicating that the operation had a positive impact on their lives.

Download Full-text

Clinical trial of combination therapy for the efficacy, safety, tolerability and improvements in quality of life in patients with moderate to severe plaque psoriasis

International Journal of Clinical Trials ◽

10.18203/2349-3259.ijct20183180 ◽

2018 ◽

Vol 5 (3) ◽

pp. 121

Author(s):

Amruthavalli G. V. ◽

Aruna V. ◽

Gayathri R.

Keyword(s):

Clinical Trial ◽

Combination Therapy ◽

Topical Therapy ◽

Clinical Manifestations ◽

Life Quality ◽

Autoimmune Disorder ◽

Severity Index ◽

Psoriatic Skin ◽

Late Night ◽

Feedback Questionnaire

Background: Psoriasis is an autoimmune disorder with clinical manifestations scales, inflammation and dryness. The psoriatic skin behaves differently in concurrence with circadian rhythm. Cell division increases in late night and early morning hours. Enzymatic activity will be more during day time. To balance these variations a 24×7 protection is required. The objective of the present study is to find the improvement in Psoriasis condition with the Combination therapy compared to single drug usage.Methods: A clinical trial for 4 weeks was conducted among psoriasis patients with psorolin oil vs. combination therapy (Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar) and the clinical relief was measured among both groups by following parameters like psoriasis area and severity index (PASI), Physician’s global assessment (PGA), dermatology life quality index (DLQI), subjective self-assessment questionnaire (SSAQ) and subject investigational product feedback questionnaire (SIPFBQ).Results: Combination therapy (1-3-2 topical therapy) of Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar as a treatment regimen was found to be more effective in the treatment of psoriasis.Conclusions: 1-3-2 topical therapy is useful in severe psoriasis conditions and recommended for long term effective treatment of psoriasis.

Download Full-text

Eczema: tactics of choice external therapy

Vestnik dermatologii i venerologii ◽

10.25208/0042-4609-2018-94-3-56-66 ◽

2018 ◽

Vol 94 (3) ◽

pp. 56-66 ◽

Cited By ~ 1

Author(s):

D. V. Zaslavsky ◽

Е. S. Tulenkova ◽

K. N. Monakhov ◽

N. A. Kholodilova ◽

Yu. S. Kondratieva ◽

...

Keyword(s):

Clinical Symptoms ◽

Demographic Data ◽

Objective Assessment ◽

Drug Application ◽

Clinical Manifestations ◽

Life Quality ◽

Clinical History ◽

Therapeutic Effects ◽

Good Tolerability ◽

Anti Inflammatory

The therapeutic effects of synthetic tannins are based on their binding action, as well as on their anti-pruritic, antimicrobial and anti-inflammatory effects. Materials and methods. A clinical study of Neotanin spray, Neotanin lotion (suspension) and Neotanin cream was carried out in 8 clinical centres during the period from June, 2017 to January, 2018. The study had an open and non-comparative character. The study included 68 patients of both sex es aged from 1 month to 80 years suffering from eczema dermatosis in the acute weeping phase, including cases with complications after secondary infections (including eczema elements localized on the face). Before the study, information on the clinical history, demographic data, co-morbidities, physical examination data of the patients was collected. The treatment regimen included 2 stages: 1) Neotanin in the spray or lotion (suspension) form 3–4 times per day during 1–5 days, up to the full drying of eczema elements; 2) Neotanin in the cream form 3 times per day, up to the disappearance of the clinical manifestations of skin dermatosis. The duration of the study ranged from 5 to 14 days: the study was completed when a patient had achieved remission. The criteria for assessing the drug efficacy were as follows: dynamics of subjective complaints, objective assessment of the patient's condition (the presence and severity of clinical symptoms), dynamics of the Dermatology Life Quality Index (DLQI). Results. Neotanin preparations showed a high efficacy in the acute and subacute stages of the inflammatory process as an antipruritic agent. Itching stopped within 5 minutes after the drug application, with the antipruritic effect lasting for an average of 3–4 hours. In 85 % of the patients, marked excoriations were absent on the 3rd day of treatment. Neotanin demonstrated a pronounced anti-inflammatory effect. In 92 % of the patients, the symptoms of erythema and edema were significantly reduced one week after the beginning of treatment, with the manifestations of inflammatory exudation being conclusively decreased. One week following the beginning of treatment, 100 % of the patients demonstrated no oozing lesions. The absence of serious undesirable effects in the patients during the study evidences to the good tolerability and safety of this drug.

Download Full-text

PILOT STUDY OF TOLL-LIKE RECEPTOR LEVEL 2 AND THYMIC STROMAL LYMPHOPOIETIN IN CHILDREN WITH ATOPIC DERMATITIS

PEDIATRIA Journal named after G N SPERANSKY ◽

10.24110/0031-403x-2021-100-2-64-71 ◽

2021 ◽

Vol 100 (2) ◽

pp. 64-71

Author(s):

O.N. Zaynullina ◽

◽

D.V. Pechkurov ◽

Z.R. Hismatullina ◽

L.V. Gankovskaya ◽

...

Keyword(s):

Atopic Dermatitis ◽

Blood Serum ◽

Clinical Manifestations ◽

Thymic Stromal Lymphopoietin ◽

Healthy Children ◽

Toll Like Receptor ◽

Receptor Level ◽

Systemic Nature ◽

Grade 3 ◽

Level 2

The aim of this study is to assess the level of Toll-like receptor level 2 (TLR-2) and thymic stromal lymphopoietin (TSLP) in the blood serum of children and to establish the relationship between these parameters and the severity of clinical manifestations of atopic dermatitis (AD) and the degree of microbial contamination of the gut. Research materials and methods: 68 children aged from 3 months to 6 years with an AD and 31 conditionally healthy children of the corresponding age were examined. Determination of the level of TLR-2 and TSLP in blood serum was carried out by enzyme immunoassay, and the composition of the intestinal microflora was assessed by MALDITOF mass spectrometry. Results: in children with AD, the median serum TLR-2 level was 2,88 [1,60; 4,91] ng/ml, TSLP – 6,01 [1,11; 9,5] pg/ml, which is statistically significantly higher than in conventionally healthy children (p<0,0001). The highest levels of TLR-2 and TSLP were found in erythematoussquamous with lichenification of the AD form – Me=6,10 [3,55; 10,62] ng/ml and Ме=12,73 [5,81; 22,70] pg/ml respectively. In children with moderate severity of AD, TLR-2 and TSLP values were statistically significantly higher (p<0,0001) compared to mild AD (Me=5,58 [2,29; 8,18] ng/ml versus 0,72 [0,22; 2,02] ng/ml and 7,48 [4,25; 12,95] pg/ml versus 0,64 [0,39; 0,75] pg/ml, respectively). The level of TLR-2 and TSLP increased with the degree of intestinal dysbiosis: Me=6,27 [4,14; 8,02] ng/ml at grade 3 dysbiosis versus 1,25 [0,46; 2,15] ng/ml at the 1st degree of dysbiosis and 16,28 [10,01; 22,6] pg/ml at the 3rd degree of dysbiosis versus 0,63 [1,33; 0,70] pg/ml at the 1st degree of dysbiosis, respectively (p<0,0001). Results: the obtained data on the activation of TLR-2 and TSLP in AD emphasize the systemic nature of the inflammatory response; however, the causal relationship between the level of TLR-2 and TSLP and AD activity requires further verification.

Download Full-text